The Importance of the Beacon Equipment for Cell Line Development: A Biotimize Exclusive in Brazil

Cell line development is a critical step in the production of biopharmaceuticals, especially in the manufacturing of therapeutic proteins like monoclonal antibodies. This process involves selecting and cultivating cells capable of producing the desired protein in large quantities and with the highest quality. The efficiency of this development directly impacts the time, cost, and success of the final product’s production.

In this context, Biotimize stands out as the only service provider company in Brazil to offer the Beacon, a cutting-edge piece of equipment developed by Berkeley Lights. The Beacon uses optofluidic technology, enabling the precise and rapid selection and analysis of individual cells. This represents a revolution in cell line development, offering unmatched advantages to our clients.

One of the main benefits of the Beacon, in addition to ensuring monoclonality, is its ability to efficiently find clones that excel in three critical areas: cell growth, productivity, and protein quality. Instead of relying on traditional methods, which can be time-consuming and less accurate, the Beacon accelerates this process, allowing the identification of the most promising cells in a matter of days.

Selecting clones that grow better and produce more protein is crucial for ensuring manufacturing efficiency in biopharmaceutical production. Additionally, the Beacon stands out by helping identify clones that produce proteins of the highest quality, which is essential to ensure the safety and efficacy of biological treatments. This precision in clone selection results in a more economical process, reducing development time and, consequently, the costs of producing the final product.

With the Beacon, Biotimize offers a solution that reduces cell line development time from months to weeks, while also optimizing productivity and product quality. This innovation positions Biotimize as a leader in biotechnology in Brazil, providing our clients with a competitive edge that can accelerate the time-to-market of new treatments.

By choosing the Beacon, biotech companies in Brazil gain access to cutting-edge technology that not only improves the efficiency of cell line development but also helps reduce costs and enhance the quality of biopharmaceuticals. This directly impacts the ability to democratize access to innovative therapies, making them available faster and at more affordable prices.

If your company is seeking excellence in biopharmaceutical development, Biotimize, with the Beacon equipment, is the ideal partner to turn your ideas into reality.